FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump
This article was originally published in The Gray Sheet
Executive Summary
FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.
You may also be interested in...
Regulatory News In Brief
FDA draft guidance explains the difference between recalls and product enhancements. Proposed rule on non-U.S. studies. More regulatory news.
News In Brief
Allergan Lap-Band unit on the block? DOJ investigates Abiomed Impella marketing. St. Jude Medical expands job cuts. More news briefs.
Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.